FDA approves new Parkinson’s treatment based on clinical trial led by USF Health faculty

[Farooqji]

apologies if already posted

usf.edu/health/news/2024/fd...

[BeedieBird]

Hmmmm, wonder how this is different from Rytary? And if it's cheaper. Rytary is expensive.

[Pixelpixie]

so frustrating that it’s all. Variations on the CL theme

[mk2002wi in reply to Pixelpixie]

True, but improvement in this area will be good. Regeneration of the neurons would be better.

[Squarepushr in reply to Pixelpixie]

yes, 'breakthrough' is not the word that comes to mind...that's as 'breakthrough' as the BeeGees doing a Christmas album this year

[mk2002wi]

CREXONT commercial launch planned in September 2024.Hopefully, it will be affordable.

[Gioc]

Quote from link:

“The new formulation is an oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.”

IMHO It is better to take these two formulations separately according to your needs as is done now in most cases.

Greetings from Italy.

The Sedum (Hylotelephium) Spectabile dont need much water!

[Sydney75]

Same pharma that brought rytary to market but rytary had patent disputes so goes generic to one manufacturer in 2026 n full generic in 2028. It looks very similar but mechanism for delay with drug encapsulation different. It will likely be $$ and not covered by Medicare

A trial of monoclonal antibodies not on market yet looked promising at slowing down PD.